Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial - Nature Medicine

Nature MedicineView source article

Part of story

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 20262 sourcesMedical imaging GLP-1 receptor agonists Novo Nordisk Clinical trials Cardiovascular diseases Randomized controlled trial Obesity Heart health Obesity treatment

$Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction$

Other sources for this story

Nature Medicine

Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial - Nature Medicine